Skip to main content
Top
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Data in longitudinal randomised controlled trials in cancer pain: is there any loss of the information available in the data? Results of a systematic literature review and guideline for reporting

Authors: Odile Sauzet, Maren Kleine, John E. Williams

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Given the prevalence of untreated pain among cancer patients, there have been calls for more and better research in the domain. Increasingly, calls for less waste and more optimal use of trial data collected are being made. Waste of data includes non-optimal statistical analysis and non-presentation of interpretable effect size as a measure of effectiveness of an intervention which also enable comparisons across studies.

Methods

We reviewed the recent literature on randomised trials on longitudinal cancer pain to identify sources of loss of data information by collecting material on the nature of outcomes collected, analysed, the method of analysis and what was presented as a result of the trial. Illustrated with real data, we propose some guidelines on how to adequately analyse longitudinal data and report the results using mixed models.

Results

We identified some major source of data information loss, one of which is the transformation of a continuous pain outcome. Not adjusting for the collected outcome baseline value is moreover a source of bias. Multiple testing by analysing the data cross-sectionnally at each time-point leads to loss of information and power. Finally, effect sizes reflecting the effectiveness of the intervention were never reported.

Conclusions

We identified several sources of information loss in the way longitudinal trials on pain were analysed and reported. However these problems could be easily solved by using regression methods like mixed models and presenting regression parameters to provide a concrete quantitative effect of the intervention.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jost L, Roila F. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol Off J Eur Soc Medl Oncol/ESMO. 2010;21 Suppl 5:v257–60.CrossRef Jost L, Roila F. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol Off J Eur Soc Medl Oncol/ESMO. 2010;21 Suppl 5:v257–60.CrossRef
2.
go back to reference Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2008;19(12):1985–91.CrossRef Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2008;19(12):1985–91.CrossRef
3.
go back to reference Fisch MJ, Lee J, Weiss M, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(16):1980–8.CrossRef Fisch MJ, Lee J, Weiss M, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(16):1980–8.CrossRef
4.
go back to reference van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol Off J Eur Soc Med Oncology/ESMO. 2007;18(9):1437–49.CrossRef van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol Off J Eur Soc Med Oncology/ESMO. 2007;18(9):1437–49.CrossRef
6.
go back to reference Gordon DB, Dahl JL, Miaskowski C, et al. American pain society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. Arch Intern Med. 2005;165(14):1574–80.CrossRefPubMed Gordon DB, Dahl JL, Miaskowski C, et al. American pain society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. Arch Intern Med. 2005;165(14):1574–80.CrossRefPubMed
7.
go back to reference Ripamonti CI, Santini D, Maranzano E, et al. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol Off J Eur Soc Med Oncology/ESMO. 2012;23 Suppl 7:vii139–54. Ripamonti CI, Santini D, Maranzano E, et al. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol Off J Eur Soc Med Oncology/ESMO. 2012;23 Suppl 7:vii139–54.
10.
go back to reference Breivik H, Borchgrevink PC, Allen SM, et al. Assessment of pain. Br J Anaesth. 2008;101(1):17–24.CrossRefPubMed Breivik H, Borchgrevink PC, Allen SM, et al. Assessment of pain. Br J Anaesth. 2008;101(1):17–24.CrossRefPubMed
12.
go back to reference Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1–2):9–19.CrossRefPubMed Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1–2):9–19.CrossRefPubMed
13.
go back to reference Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Ann Intern Med. 2009;151(4):264-W64.CrossRef Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Ann Intern Med. 2009;151(4):264-W64.CrossRef
14.
go back to reference Williams J, Peacock JL, Gubbay A, et al. Routine screening for pain combined with a pain treatment protocol in patients with cancer: a randomized controlled trial. Br J Anaesth. 2015;115(4):621–8.CrossRefPubMed Williams J, Peacock JL, Gubbay A, et al. Routine screening for pain combined with a pain treatment protocol in patients with cancer: a randomized controlled trial. Br J Anaesth. 2015;115(4):621–8.CrossRefPubMed
16.
go back to reference Ragland DR. Dichotomizing continuous outcome variables: dependence of the magnitude of association and statistical power on the cutpoint. Epidemiology. 1992;3(5):434–40.CrossRefPubMed Ragland DR. Dichotomizing continuous outcome variables: dependence of the magnitude of association and statistical power on the cutpoint. Epidemiology. 1992;3(5):434–40.CrossRefPubMed
17.
go back to reference Twisk JWR. Applied longitudinal data analysis for epidemiology: A practical guide. Cambridge: Cambridge Medicine; 2013. Twisk JWR. Applied longitudinal data analysis for epidemiology: A practical guide. Cambridge: Cambridge Medicine; 2013.
18.
go back to reference Sauzet O, Kleine M, Menzel-Begemann A, et al. Longitudinal randomised controlled trials in rehabilitation post-stroke: a systematic review on the quality of reporting and use of baseline outcome values. BMC Neurol. 2015;15(1):99.CrossRefPubMedPubMedCentral Sauzet O, Kleine M, Menzel-Begemann A, et al. Longitudinal randomised controlled trials in rehabilitation post-stroke: a systematic review on the quality of reporting and use of baseline outcome values. BMC Neurol. 2015;15(1):99.CrossRefPubMedPubMedCentral
Metadata
Title
Data in longitudinal randomised controlled trials in cancer pain: is there any loss of the information available in the data? Results of a systematic literature review and guideline for reporting
Authors
Odile Sauzet
Maren Kleine
John E. Williams
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2818-8

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine